Pharmaceutical Treatment Options for Patients with Hormone Refractory

1,112 views
1,072 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,112
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pharmaceutical Treatment Options for Patients with Hormone Refractory

  1. 1. PHARMACEUTICAL TREATMENT OPTIONS FOR PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
  2. 2. There are a number of pharmaceuticals now available for the treatment of patients with prostate cancer. Chief among those is prednisone, an immune response suppressor often used in conjunction with other oncology drugs to treat a wide variety of cancers. In the case of patients who have prostate cancer that is resistant to hormone therapy (hormone refractory), the options narrow considerably.
  3. 3. One fairly new treatment is acetone acetate (Zytiga), which has gained FDA approval for the treatment of patients with metastasized hormone refractory prostate cancer. When used with prednisone, acetone acetate has been shown to be effective in inhibiting an enzyme (17 a-hydroxylase/C17,20- lyase) necessary for angrogen biosynthesis that is expressed in prostate cancer cells. Other treatment options for patients with hormone refractory prostate cancer include Cabazitaxel, Docetaxel, and Sipuleucel-T. Zytiga was first developed by Cougar Pharmaceuticals, Inc., a biopharmaceutical company founded by Dr. Lindsay Rosenwald. Dr. Rosenwald has also been instrumental in securing FDA approval for the drugs Trisenox and Milnacipran.
  4. 4. Be sure to thoroughly discuss all treatments and possible side effects with your doctor before deciding which option is best for you.

×